Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Allostery Investments LP

Q2 2025 · 13F-HR

Allostery Investments LPholdings as filed

Filed 2025-08-14 · accession 0001013594-25-001022

$7.9M
Reported value
20
Positions
2025-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
00370M103ABVXABIVAX SA$1.3M16.3%167,350CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$1.2M15.3%22,500CommonSOLE
03237H101AMLXAMYLYX PHARMACEUTICALS INC$769,9639.81%120,119CommonSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$689,8508.79%52,500CommonSOLE
30052C107EOLSEVOLUS INC$552,6007.04%60,000CommonSOLE
76200L309RZLTREZOLUTE INC$532,0516.78%119,294CommonSOLE
N5749R1002GHMERUS N V$473,4006.03%9,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$452,2005.76%40,000CommonSOLE
359616109FULCFULCRUM THERAPEUTICS INC$277,6293.54%40,353CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$260,5803.32%6,000CommonSOLE
925050106VRNAVERONA PHARMA PLC$236,4503.01%2,500CommonSOLE
87583X109TNGXTANGO THERAPEUTICS INC$204,8002.61%40,000CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$172,7202.20%4,000CommonSOLE
23282W605CYTKCYTOKINETICS INC$165,2002.10%5,000CommonSOLE
89157D105TRMLTOURMALINE BIO INC$149,6021.91%9,356CommonSOLE
52490G102LEGNLEGEND BIOTECH CORP$141,9601.81%4,000CommonSOLE
640268306NKTRNEKTAR THERAPEUTICS$103,3601.32%4,000CommonSOLE
74346M406PMNEURPROMIS NEUROSCIENCES INC$76,3030.97%155,720CommonSOLE
03940C100ACLXGBXARCELLX INC$65,8500.84%1,000CommonSOLE
05338F306AVTXAVALO THERAPEUTICS INC$44,9100.57%9,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.